Search research articles
Contact Us
Filters
Showing results (1-10 of 11) with videos related to
Page
of 2
Sort By:
JAMA Psychiatry
|
December 23, 2025
Restricting Liafensine on the Basis of ANK3 Genotype-More Evidence Needed-Reply
Gang Wang, Matthew A Spear, Wen Luo
Medical Oncology (Northwood, London, England)
|
September 13, 2007
Phase I/II study of IV topotecan in combination with whole brain radiation for the treatment of brain metastases
Alireza Mirmiran, Edward McClay, Matthew A Spear
Current Drug Targets
|
July 23, 2011
Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic
Matthew A Spear, Patricia LoRusso, Alain Mita, et al.
Medical Oncology (Northwood, London, England)
|
October 5, 2006
Focal radiation therapy of brain metastases after complete surgical resection
Gautam Bahl, Greg White, John Alksne, et al.
Investigational New Drugs
|
February 18, 2011
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
Michael Millward, Paul Mainwaring, Alain Mita, et al.
Journal of Virological Methods
|
November 26, 2002
HSV-1 amplicon peptide display vector
Matthew A Spear, Deborah Schuback, Kenichi Miyata, et al.
Journal of Pediatric Hematology/Oncology
|
May 14, 2005
Temozolomide and radiation for aggressive pediatric central nervous system malignancies
Kenneth C Loh, Jennifer Willert, Hal Meltzer, et al.
JAMA Psychiatry
|
September 10, 2025
ANK3 as a Novel Genetic Biomarker for Liafensine in Treatment-Resistant Depression: The ENLIGHTEN Randomized Clinical Trial
Gang Wang, Mario Aguado, Matthew A Spear, et al.
Investigational New Drugs
|
November 15, 2011
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
Michael Millward, Timothy Price, Amanda Townsend, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2010
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas
Monica M Mita, Matthew A Spear, Lorrin K Yee, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 11) with videos related to
Sort By:
Page
of 2
JAMA Psychiatry
|
December 23, 2025
Restricting Liafensine on the Basis of ANK3 Genotype-More Evidence Needed-Reply
Gang Wang, Matthew A Spear, Wen Luo
Medical Oncology (Northwood, London, England)
|
September 13, 2007
Phase I/II study of IV topotecan in combination with whole brain radiation for the treatment of brain metastases
Alireza Mirmiran, Edward McClay, Matthew A Spear
Current Drug Targets
|
July 23, 2011
Vascular disrupting agents (VDA) in oncology: advancing towards new therapeutic paradigms in the clinic
Matthew A Spear, Patricia LoRusso, Alain Mita, et al.
Medical Oncology (Northwood, London, England)
|
October 5, 2006
Focal radiation therapy of brain metastases after complete surgical resection
Gautam Bahl, Greg White, John Alksne, et al.
Investigational New Drugs
|
February 18, 2011
Phase 1 study of the novel vascular disrupting agent plinabulin (NPI-2358) and docetaxel
Michael Millward, Paul Mainwaring, Alain Mita, et al.
Journal of Virological Methods
|
November 26, 2002
HSV-1 amplicon peptide display vector
Matthew A Spear, Deborah Schuback, Kenichi Miyata, et al.
Journal of Pediatric Hematology/Oncology
|
May 14, 2005
Temozolomide and radiation for aggressive pediatric central nervous system malignancies
Kenneth C Loh, Jennifer Willert, Hal Meltzer, et al.
JAMA Psychiatry
|
September 10, 2025
ANK3 as a Novel Genetic Biomarker for Liafensine in Treatment-Resistant Depression: The ENLIGHTEN Randomized Clinical Trial
Gang Wang, Mario Aguado, Matthew A Spear, et al.
Investigational New Drugs
|
November 15, 2011
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination
Michael Millward, Timothy Price, Amanda Townsend, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 9, 2010
Phase 1 first-in-human trial of the vascular disrupting agent plinabulin(NPI-2358) in patients with solid tumors or lymphomas
Monica M Mita, Matthew A Spear, Lorrin K Yee, et al.
Page
of 2